Arrowhead Pharmaceuticals (ARWR) News Today $16.42 +0.36 (+2.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$16.41 -0.01 (-0.06%) As of 08/8/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Arrowhead Pharmaceuticals Up Today?Toggle Visibility of Why Is Arrowhead Pharmaceuticals Up Today?Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock movement today reflects a combination of analyst forecast revisions and mixed Q3 results. Positive Sentiment: Leerink Partnrs raised its FY2026 earnings per share estimate for ARWR to ($1.62) from ($1.66), signaling an improved long-term outlook. What is Leerink Partnrs' Forecast for ARWR FY2026 Earnings? Neutral Sentiment: Royal Bank of Canada maintained an “outperform” rating on ARWR but trimmed its price target from $40.00 to $38.00, still implying over 130% upside. Benzinga Neutral Sentiment: Arrowhead published its fiscal Q3 2025 results, updating investors on revenue, R&D progress and clinical milestones. Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results Negative Sentiment: Q3 revenue dropped 41% year-over-year to $27.8 million, reflecting softer commercial performance. Arrowhead (ARWR) Q3 Revenue Drops 41% Negative Sentiment: ARWR missed Q3 EPS expectations, reporting ($1.26) versus consensus of ($0.94). View Press Release Negative Sentiment: Leerink Partnrs lowered its FY2025 EPS forecast for ARWR to $1.15 from $1.35, dialing back near-term profitability projections. FY2025 Earnings Forecast for ARWR Issued By Leerink Partnrs Posted 1+ days agoAI Generated. May Contain Errors. ARWR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call TranscriptAugust 8 at 9:00 PM | seekingalpha.comARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS…August 8 at 8:31 PM | finance.yahoo.comWhat is Leerink Partnrs' Forecast for ARWR FY2026 Earnings?August 8 at 9:58 AM | marketbeat.comArrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter ResultsAugust 8 at 5:28 AM | finance.yahoo.comArrowhead (ARWR) Q3 Revenue Drops 41%August 7 at 5:37 PM | fool.comFY2025 Earnings Forecast for ARWR Issued By Leerink PartnrsAugust 7 at 7:30 AM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Privium Fund Management B.V.August 3, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)August 3, 2025 | marketbeat.comGSA Capital Partners LLP Buys 60,018 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)August 2, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.71 Consensus Price Target from BrokeragesAugust 2, 2025 | americanbankingnews.comArrowhead unit sells rights for plozasiran to Sanofi in Greater ChinaAugust 1, 2025 | msn.comArrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on ThursdayAugust 1, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough DealJuly 31, 2025 | finance.yahoo.comTD Cowen Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to Strong-BuyJuly 31, 2025 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 30, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded by TD Cowen to Strong-Buy RatingJuly 29, 2025 | marketbeat.comArrowhead, Sarepta Advance on PactJuly 28, 2025 | baystreet.caPinnacle Associates Ltd. Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 27, 2025 | marketbeat.comArrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta TherapeuticsJuly 25, 2025 | finance.yahoo.comArrowhead expects Sarepta to honor financial obligationsJuly 25, 2025 | msn.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 9.5% - Here's What HappenedJuly 24, 2025 | marketbeat.comMutual of America Capital Management LLC Sells 47,305 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 24, 2025 | marketbeat.comBank of New York Mellon Corp Sells 54,019 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 22, 2025 | marketbeat.comArrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter ResultsJuly 21, 2025 | businesswire.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Sees Large Volume Increase - Time to Buy?July 21, 2025 | marketbeat.comLouisiana State Employees Retirement System Has $757,000 Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 20, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Downgraded by Wall Street Zen to HoldJuly 19, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 9% - Here's WhyJuly 19, 2025 | marketbeat.comCenterBook Partners LP Sells 283,560 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 18, 2025 | marketbeat.comEdgestream Partners L.P. Increases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 16, 2025 | marketbeat.comPrincipal Financial Group Inc. Has $8.01 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 16, 2025 | marketbeat.comAmalgamated Bank Cuts Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)July 11, 2025 | marketbeat.comArrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial HypercholesterolemiaJuly 8, 2025 | businesswire.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 5, 2025 | marketbeat.comState of Alaska Department of Revenue Increases Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)June 28, 2025 | marketbeat.comARWR Arrowhead Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comArrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of PlozasiranJune 23, 2025 | finance.yahoo.comAssenagon Asset Management S.A. Has $289,000 Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)June 20, 2025 | marketbeat.com68,346 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Bought by SG Americas Securities LLCJune 19, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Pinion Investment Advisors LLCJune 15, 2025 | marketbeat.comRhumbline Advisers Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)June 14, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Buy at Wall Street ZenJune 14, 2025 | marketbeat.comGAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)June 12, 2025 | marketbeat.comResearch Analysts Set Expectations for ARWR FY2026 EarningsJune 11, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded by Wall Street Zen to Buy RatingJune 6, 2025 | marketbeat.comJim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”June 5, 2025 | msn.comJim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'June 4, 2025 | benzinga.comArrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a StudyJune 2, 2025 | insidermonkey.comSquarepoint Ops LLC Has $1.62 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)May 31, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 6.2% - Should You Buy?May 30, 2025 | marketbeat.com Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.150.50▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼167▲ARWR Articles Average Week Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BridgeBio Pharma News Verona Pharma PLC American Depositary Share News Blueprint Medicines News Roivant Sciences News Grifols News Legend Biotech News Elanco Animal Health News Revolution Medicines News Regencell Bioscience News Rhythm Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts